These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25259546)

  • 1. Time of administration important? Morning versus evening dosing of valsartan.
    Zappe DH; Crikelair N; Kandra A; Palatini P
    J Hypertens; 2015 Feb; 33(2):385-92. PubMed ID: 25259546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
    Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
    Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study.
    Ruilope LM; Heintz D; Brandão AA; Stolt P; Kandra A; Santonastaso M; Khder Y
    Blood Press Monit; 2005 Apr; 10(2):85-91. PubMed ID: 15812256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study.
    Kasiakogias A; Tsioufis C; Thomopoulos C; Andrikou I; Aragiannis D; Dimitriadis K; Tsiachris D; Bilo G; Sideris S; Filis K; Parati G; Stefanadis C
    J Hypertens; 2015 Feb; 33(2):393-400. PubMed ID: 25318654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
    Destro M; Crikelair N; Yen J; Glazer R
    Vasc Health Risk Manag; 2010 Sep; 6():821-7. PubMed ID: 20859551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
    Pool JL; Glazer R; Crikelair N; Levy D
    Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
    Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
    Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
    Sharma AM; Davidson J; Koval S; Lacourcière Y
    Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
    Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
    Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained antihypertensive activity of telmisartan compared with valsartan.
    Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
    Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
    Eguchi K; Kario K; Hoshide Y; Hoshide S; Ishikawa J; Morinari M; Ishikawa S; Shimada K
    Am J Hypertens; 2004 Feb; 17(2):112-7. PubMed ID: 14751651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
    Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
    J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.